EDIT earnings call for the period ending June 30, 2019.
News & Analysis: Editas Medicine
With a new CEO in place and a groundbreaking "in vivo" dosing study approaching, the gene-editing leader is rightly excited for the future.
The gene-editing approach might prove more useful outside the clinic.
The field expanded into a new therapeutic area, and fell back into a bitter dispute over intellectual property.
High risk? Definitely. But this small biotech also has the potential for high returns over the long run.
Seven simple steps to improving your chances of success in this part of the market.
Precision BioSciences raised over $170 million in net proceeds from its initial public offering in late March.
They might be this year's Bad News Bears, but I think these three stocks will be long-term winners.
First-quarter earnings results from three gene-editing companies gave Wall Street analysts pause.
They're risky. You'll have to wait years before any significant revenue comes in. But these biotech stocks could be huge winners.